What is UBT251 studying for people with overweight or obesity?

UBT251 is being studied to see if it is safe and effective for adults living with overweight or obesity. Researchers want to learn how different doses affect body weight and tolerability. The study is sponsored by Novo Nordisk A/S and aims to provide more information about this treatment option.

Who may be eligible for this overweight or obesity clinical trial?

Adults aged 18 to 65 years who are living with overweight or obesity may be eligible. Both males and females can participate. Important factors include not having used certain weight-related medications recently and no known allergies to the study drugs. Please review eligibility criteria for more details.

Is there any cost to participate in this overweight or obesity clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel-related costs.

Actively Recruiting

Phase 2

Age: 18Years - 65Years

All Genders

ID07395687

A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity

Led by Novo Nordisk A/S · Updated on 2026-04-21

333

Participants Needed

Research Sites

5 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying the safety and effectiveness of UBT251 for people living with overweight or obesity. This clinical trial is a phase 2 study that compares different doses of UBT251 against a placebo, which contains no active medicine. The goal is to understand how UBT251 affects body weight and tolerability in adults with these conditions. Participants will be randomly assigned to receive various doses of UBT251 or a placebo, all given as injections under the skin of the abdomen. The study includes multiple parts where participants receive different dose levels, with some receiving a single dose and others multiple doses. Placebo injections are designed to look like UBT251 to maintain study blinding. During the trial, participants will be monitored for treatment-emergent adverse events and changes in body weight over several weeks. Blood samples will be taken to measure UBT251 levels in the body. The study involves regular visits for assessments including physical exams, vital signs, and lab tests, extending up to 33 weeks. Researchers will track safety, tolerability, and how the drug moves through the body to evaluate outcomes.

CONDITIONS

Brief Title

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Who Can Participate

Age: 18Years - 65Years

All Genders

Eligibility Criteria

You may qualify if you...

Male or female (sex at birth)
For Part C: Japanese, Chinese, or non-Asian participants with both parents of matching descent
Age at informed consent: 18-55 years for Part A and Part C; 18-65 years for Part B
Body mass index (BMI) at screening: 27.0-39.9 kg/m² for Part A; 30.0-50.0 kg/m² for Part B; 24-34.9 kg/m² for Part C
Eligible based on medical history, physical exam, vital signs, ECG, and lab tests as judged by the investigator

You will not qualify if you...

Known or suspected allergy to study drug or related products
Use of medications containing GLP-1, GIP, or glucagon receptor agonists within 90 days before screening
Any condition or unwillingness that may risk safety or protocol compliance as judged by the investigator

Research Team

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here